Diabetes Care in The Netherlands: - Novo Nordisk

Main conclusionsObjectiveFurther improvehealth forpatients andsociety11Diabetes is a is challenging a challenging disease disease for patients, for patients, and a major and and a major underestimated and source ofmedical underestimated costs and lost source productivity of medical for society costs and lost productivity for society• 1.0-1.1M 1.0-1.1M diabetes diabetes patients patients (~100,000 (~100,000 more diagnosed more diagnosed patients patients than reported) than reported)• EUR 4-5 EUR B total 4 -5 medical B total costs medical for costs diabetes for diabetes patients, patients, of which of EUR which 2.5 EUR B costs 2.5 for B costs diabetestreatment for and diabetes complications treatment (more and complications than double of (more reported). than On double top of that reported). EUR 6 On B lost topproductivity of that EUR 6 B lost productivity• Total costs Total could costs rise could to EUR rise 16-19 to EUR B 16 in 2020 -19 B in 2020• Diabetes care in The Netherlands has reached a high level of quality, but22Diabetes care in The Netherlands has reached a high level of quality, but there is stillopportunity there is still for further opportunity improvement for further improvementFurther improving health of diabetes patients may lead to EUR 1.5 -2 B ofeconomic benefits in 2020 (less medical costs and higher productivity)33Further improving health of diabetes patients may lead to EUR 1.5-2 B of economic benefits in2020 (less medical costs and higher productivity)Insurers and governments should adjust certain economic incentives to11 Refine stimulate economic high incentives quality to care encourage integrated care and quality improvementThe roadFewer barriersfor quality in ourhealth caresystemTo increase labour participation, government and companies can invest indiabetes care via collective insurance models22Engage employers, UWV and participative care in diabetes care3 Engage the patient’s social network to support self managementInsurers , patient federations and Pharma companies could facilitate34 Introduce conditional market access models for new therapies and medication to assessnetwork solutions around the patient to support better diabetes carebehavioural impact4Government and insurers could introduce temporary medication marketaccess models to assess impact on therapy complianceBooz & Company 14 November 201110Prepared for Novo Nordisk2